Boston Scientific Corp (BSX)vsIRIDEX Corporation (IRIX)
BSX
Boston Scientific Corp
$46.04
-0.04%
HEALTHCARE · Cap: $63.87B
IRIX
IRIDEX Corporation
$0.86
-1.95%
HEALTHCARE · Cap: $15.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 39107% more annual revenue ($20.61B vs $52.58M). BSX leads profitability with a 17.3% profit margin vs -6.2%. BSX appears more attractively valued with a PEG of 0.54. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
IRIX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.2%
Fair Value
$37.36
Current Price
$46.04
$8.68 premium
Margin of Safety
+75.3%
Fair Value
$5.79
Current Price
$0.86
$4.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Growing faster than its price suggests
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a mature stock while IRIX is a turnaround play — different risk/reward profiles.
IRIX carries more volatility with a beta of 0.64 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 32/100), backed by strong 17.3% margins and 11.6% revenue growth. IRIX offers better value entry with a 75.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?